

Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies

Shaji Kumar, Thomas E. Witzig, and S. Vincent Rajkumar

From the Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN.

Submitted October 21, 2003; accepted February 20, 2004.

Supported in part by grants CA85818, CA93842, CA100080, and CA62242 from the National Cancer Institute, Bethesda, MD. Also supported in part by the Multiple Myeloma Research Foundation, the Goldman Philanthropic Partnerships, and the Leukemia and Lymphoma Society.

The authors have received research support for clinical trials using thalidomide from Celgene.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: rajks@mayo.edu.

© 2004 by American Society of Clinical Oncology

0732-183X/04/2212-2477/\$20.00

DOI: 10.1200/JCO.2004.10.127

ABSTRACT

Thalidomide, initially introduced as a sedative, was withdrawn from the market in the early 1960s after it was found to be a teratogen. However, it later found use as an investigational agent in the treatment of erythema nodosum leprosum, oral ulcers, graft versus host disease, and wasting associated with the human immunodeficiency syndrome. Its antiangiogenic properties were recognized in the early 1990s during a period where the importance of angiogenesis became increasingly apparent as a critical step in the proliferation and spread of malignant neoplasms. This led to the evaluation of thalidomide as an antiangiogenic agent in the treatment of several cancers. Thalidomide has already become part of standard therapy for the treatment of patients with relapsed and refractory multiple myeloma. It has also been found to have varying degree of benefit in various other malignancies. Although more clinical trials are needed, Kaposi's sarcoma and myelofibrosis represent other malignancies in which thalidomide has already demonstrated promising activity. The mechanism of action of thalidomide in cancer is still unclear, but do appear to be mediated by several other mechanisms in addition to its anti-angiogenic properties. This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies.

J Clin Oncol 22:2477-2488. © 2004 by American Society of Clinical Oncology

Thalidomide was first marketed as a sedative in the 1950s and withdrawn from the market following reports of teratogenicity in 1961.^{1,2} Since that time, new uses for the drug have emerged, including the treatment of erythema nodosum leprosum,³ aphthous ulcers of Behcet's disease,⁴ wasting and oral ulcers associated with the human immunodeficiency syndrome,^{5,6} and graft versus host disease.⁷ These indications allowed continued availability of thalidomide in a restricted manner, primarily through clinical trials and for compassionate use. In 1998, the United States Food and Drug Administration approved thalidomide for use in erythema nodosum leprosum. Access to thalidomide in the United States requires participation in the System for Thalidomide Education and Prescription Safety (STEPS) program to prevent teratogenicity.⁸

Recently numerous studies have shown that thalidomide has significant activity in the treatment of multiple myeloma.⁹⁻¹¹ In

fact, myeloma has rapidly become the most common indication for the use of thalidomide in clinical practice. Recent reviews have summarized the role of thalidomide in myeloma and related plasma cell malignancies.^{12,13} Besides myeloma, clinical trials have been conducted with the drug in several hematologic and nonhematologic malignancies as well. These trials have shed light on other promising aspects of thalidomide in the treatment of cancer. This review summarizes the available literature on the use of thalidomide in non-plasma-cell malignancies and the current role of thalidomide in these disorders.

Brief Historical Overview

Soon after its teratogenic properties were detected, oncologists were hopeful that the powerful inhibitory effect of thalidomide on growing fetal tissues can be redirected for cancer therapy.¹⁴ This interest in studying thalidomide as an anticancer agent led to at least three trials in the early 1960s.^{15,16} The Eastern Cooperative Oncol-

ogy Group studied 21 patients with 14 types of advanced cancer, including two with myeloma at doses ranging between 600 and 2,000 mg/d.¹⁶ Subjective palliation of symptoms was noted in one-third of the patients. However, other than minimal slowing of tumor growth in two patients with rapidly progressive disease, no significant antitumor effects could be discerned. In another study, thalidomide was evaluated in 71 patients with a variety of cancers at doses ranging from 300 to 2,000 mg/d.¹⁵ Except for resolution of pulmonary metastasis in a patient with renal cell carcinoma, no other responses were seen. There was at least one other negative study conducted during that time period. Following these initial unimpressive trials, there was little enthusiasm regarding thalidomide as an antineoplastic agent until the late 1990s.

The resurgence of interest in this drug as an antineoplastic agent in the last decade coincided with two key scientific observations. One was the heightened appreciation of the role of angiogenesis in cancer biology,^{17,18} especially after the discovery of angiostatin and endostatin, two potent antiangiogenic compounds.^{19,20} The other was the discovery that thalidomide possessed potent antiangiogenic properties.^{21,22} Angiogenesis (sprouting of new microvasculature from existing blood vessels) is critical for the proliferation and metastases of most malignant neoplasms. In its absence, tumors cannot grow beyond 1 to 2 mm in size.¹⁸ Based on the increased angiogenesis noted in myeloma, researchers at the University of Arkansas tested the role of thalidomide in 84 patients with relapsed and refractory myeloma.⁹ They observed a 32% response rate, including two complete remissions (CRs), in this heavily pretreated population, making thalidomide the first new agent for myeloma in over three decades. Although clinical trials with the drug in several tumors were already ongoing, it was this dramatic effect in myeloma that ushered thalidomide as a legitimate anticancer agent for further research.

Pharmacology

Thalidomide (α -N-[phthalimido] glutarimide, C₁₃ H₁₀ N₂ O₄), is a glutamic acid derivative and contains a glutarimide moiety with a single chiral center. It is formulated as a racemic mixture of the two optically active S (–) and R (+) enantiomers. These enantiomers can rapidly interconvert at physiologic pH and have different biologic effects—the S enantiomer being primarily responsible for the teratogenic effects, and the R enantiomer for the sedative properties.²³

At present, thalidomide is only available as an oral formulation. Poor water solubility of this compound and the lack of an intravenous formulation have hampered reliable pharmacokinetic studies of this agent. However, healthy volunteer studies as well as studies in HIV patients and patients with prostate cancer have shown that the time to peak concentration varies from 3 to 6 hours, indicating a slow absorption.^{24–26} Though there is reasonable corre-

lation between the dose and the area under the curve, significant variability is seen in the maximum concentration, probably reflecting its poor absorption.²⁷ There is no significant drug binding by plasma proteins, and it has a large apparent volume of distribution as noted in human and animal studies.^{25,26} It has been shown to be present in semen after a period of 4 weeks of therapy and levels appear to correlate with serum levels.²⁸

The majority of the drug appears to undergo spontaneous nonenzymatic hydrolytic cleavage in the blood circulation into over 12 metabolites, many of which are metabolically active. Though in vitro studies in rats suggest a role for the cytochrome P450 system in its metabolism, human studies have so far failed to demonstrate any significant hepatic metabolism.^{29,30} However, in an immunodeficient mouse myeloma model, thalidomide demonstrated efficacy only in the presence of implanted human liver tissue.³¹ Differences have been noted in terms of the drug metabolism between mice and humans.³²

Elimination of thalidomide is mainly by the spontaneous hydrolysis, which occurs in all body fluids, with an apparent mean clearance of 10 l/h for the (R)-enantiomer and 21 l/h for the (S)-enantiomer in adult subjects.³³ This leads to higher blood concentrations of the (R)-enantiomer compared to those of the (S)-enantiomer. The mean elimination half-life of both enantiomers is about 5 hours. The pharmacokinetics of thalidomide in individuals with hepatic and renal dysfunction remains poorly understood. No induction of its own metabolism has been noted with prolonged use.³⁴ Thalidomide and its metabolites are rapidly eliminated in the urine, with none of the parent compound detected in the urine 48 hours following a single dose.

Adverse Effects and Dose

Teratogenicity is the most feared adverse event, and occurs when taken between days 27 and 40 of gestation.^{35,36} Fetal abnormalities include malformed and markedly shortened extremities (phocomelia) and deformities of the ears, eyes, and the gastrointestinal tract. In the United States, thalidomide (Thalomid, Celgene Corporation, Warren, NJ) is marketed under STEPS program to prevent teratogenic complications. Under this program, women in the childbearing age group must undergo pregnancy testing before starting therapy, and every 2 to 4 weeks during treatment. They must abstain from sexual intercourse, or use two highly effective contraceptive methods, during treatment. Males must abstain from sexual intercourse or use a condom while on treatment even if they have had a successful vasectomy. All patients must continue the above measures for at least 1 month following the last dose of the drug. Breast-feeding is contraindicated while on the drug.

In addition to its teratogenic potential, thalidomide therapy is associated with many other potential side effects (Table

Table 1. Adverse Effects of Thalidomide Therapy

Frequent Side Effects	Less Common Side Effects
Birth defects	Headache
Drowsiness and somnolence	Confusion
Skin rash	Malaise
Constipation	Asthenia
Peripheral neuropathy	Hyper- or hypoglycemia
Xerostomia	Tremor
Orthostatic hypotension and dizziness	Pruritus
Neutropenia	Peripheral edema
	Hepatitis (elevated serum transaminases)
	Stevens-Johnson syndrome
	Impotence
	Deep vein thrombosis
	Hair loss
	Loss of libido
	Nausea
	Fever
	Menstrual abnormalities
	Hypothyroidism

1). The frequency, management, and prevention of these adverse events has been recently reviewed.³⁷ In general, at doses below 400 mg/d, thalidomide is well tolerated. Most side effects are mild or moderate in severity (Table 1), and can be controlled by appropriate dose reduction. Sedation, fatigue, skin rash, and constipation are among the most commonly encountered side effects. Since severe constipation is a common problem, prophylactic laxatives are recommended routinely. Minor to moderate skin eruptions were noted in nearly half of patients taking thalidomide alone or with dexamethasone in one review.³⁸ These included morbilliform, seborrheic, maculopapular, or nonspecific dermatitis. Thalidomide should be discontinued if symptomatic skin rash appears, and restarted at a lower dose after it clears. Rarely, severe dermatologic reactions like Stevens-Johnson syndrome, erythema multiforme, or toxic epidermal necrolysis occur and preclude any further use of the drug.³⁹ Longer-term use of thalidomide (usually over 6 months) can cause peripheral neuropathy. Less common side effects include bradycardia, impotence, neutropenia, menstrual irregularities, edema, increased liver enzymes, deep vein thrombosis, hyper- or hypoglycemia, and hypothyroidism. Thromboembolic events appear to be higher when used along with other chemotherapy agents or dexamethasone.⁴⁰⁻⁴³ Hyperkalemia has been reported in patients with myeloma and renal failure.⁴⁴

The optimal dosing schedule for thalidomide as an antineoplastic agent is not known. Most of the clinical trials in cancer have used doses between 200 and 800 mg/d, taken orally as a single dose at bedtime. The usual starting dose in myeloma trials has been 200 mg/d, increased by 200 mg every 2 weeks to a maximum of 800 mg/d, final dose deter-

mined by the toxicity profile. The optimal dose for each patient is probably the highest dose that patients can tolerate with the minimum of side effects, which in most patients is between 200 and 400 mg/d. It is not clear if a definite dose response relationship exists, or whether smaller doses can be equally effective with lesser side effects. At least in the setting of myeloma, some studies have suggested the possibility of a dose-response effect.⁴⁵

Mechanism of Action

Clues to the mechanism of action of thalidomide in cancer probably lie in its potent teratogenic ability, but have been difficult to unravel due to several reasons. First, mechanistic studies with thalidomide are complicated by its enantiomeric inter-conversion and spontaneous cleavage to many metabolites.³³ Second, thalidomide probably requires some form of metabolic activation, since in vitro assays show modest or negligible activity, compared to highly potent effects in vivo.^{30,46} Third, no specific receptor has been identified for any of the drug's myriad of clinical effects, including toxicities such as sedation and constipation. Finally, various effects in animal models appear to be highly dependent on species and route of administration, making correlations to humans complicated and unreliable.²²

Many mechanisms have been put forth to explain the antineoplastic activity of thalidomide; and myeloma has been particularly well studied (Fig 1). Although the direct in vitro effects of thalidomide on tumor cells are unimpressive, it is felt that thalidomide targets both the cancer cell and its microenvironment. D'Amato et al²¹ and Kenyon et al²² showed that thalidomide is a potent antiangiogenic agent using in vivo models of angiogenesis. Animal studies support this hypothesis since thalidomide treatment can decrease vascular density in granulation tissue.⁴⁷ Studies suggest that a hepatic metabolite of thalidomide may be responsible for its antiangiogenic effects.⁴⁶ Despite its known antiangiogenic properties, there has been some debate about whether this is involved in the antitumor effects of thalidomide.

Based on the studies done in the context of erythema nodosum leprosum, thalidomide has been shown to have an anti-tumor necrosis factor- α (TNF- α) action.⁴⁸ Thalidomide inhibits the production of TNF- α by enhancing the degradation of TNF- α mRNA.⁴⁸ It may also bind to and increase the effect of α 1-acid glycoproteins, which possess intrinsic anti-TNF- α activity.^{49,50} In the setting of myeloma, anti-TNF- α activity may play a role. High pretreatment TNF- α levels appear to predict progression-free survival after thalidomide in patients with myeloma.⁵¹ In addition, DNA polymorphisms involving the TNF- α gene have been correlated with response to thalidomide in myeloma.⁵²

The antitumor properties are also probably related to its immunomodulatory effects and effects of cellular adhesion molecules. Thalidomide has direct effects on the T-lymphocytes stimulating cytotoxic T-cell proliferation,




Fig 1. Proposed mechanism of action of thalidomide in cancer illustrated using myeloma as an example. Thalidomide inhibits angiogenesis, enhances effects of the immune system, inhibits binding of tumor cells to stroma, and inhibits various cytokines. Thalidomide may also have direct effects on the tumor. NK, natural killer; TNF, tumor necrosis factor; IL-6, interleukin-6; VEGF, vascular endothelial growth factor; NF- κ B, nuclear factor kappa B.

and induction of secretion of interferon- γ and interleukin-2 (IL-2).⁵³ In healthy male volunteers given 200 mg/d for 4 days, it significantly decreased the circulating T-helper to T-suppressor cell ratio.⁵⁴ It also induces T-helper cell type 2 cytokine production in human peripheral blood mononuclear cell cultures, while concomitantly inhibiting T helper cell type 1 cytokine production.⁵⁵ Some of its antitumor activity of thalidomide and its derivatives may be mediated by modulation of natural-killer cell activity.⁵⁶ Thalidomide can modulate the expression of cell surface adhesion molecules like TNF- α , intercellular adhesion molecule-1 (CD54), vascular cellular adhesion molecule-1 (CD106), E-selectin and L-selectin (CD62L).⁵⁷ Other suggested mechanisms for antitumor effects include inhibition of nuclear factor-kappa B activity through suppression of I-kappa B kinase activity and inhibition of the cyclooxygenase 1 and 2 enzymes.^{58,59}

The mechanism of action of thalidomide including effects on tumor microenvironment, vascular endothelial growth factor (VEGF), plasma cell apoptosis, and angiogenesis are all being actively investigated.⁴⁹ Although it is tempting to believe that the drug has several effects at various stages of tumor growth and dissemination, we think

that it is more likely that a single as yet unidentified target is involved, given that the mechanisms discussed above are in general important in almost all cancers, while responses seen with this agent occur in very selected tumor types.

Solid Tumors

Thalidomide has been investigated in several solid tumors with variable degrees of success. Table 2 summarizes the results of published clinical trials with thalidomide in solid tumors.

Malignant Melanoma

Thalidomide used alone in a low dose did not produce any response among patients with metastatic melanoma.⁶⁴ Even at higher doses, thalidomide when used alone has led to disappointing results.⁷⁸ Thus, most of the recent studies have used thalidomide in combination with other active agents such as dacarbazine or temozolomide (TMZ) in the treatment of metastatic disease. Hwu et al⁷⁹ studied thalidomide in combination with temozolomide in patients with unresectable stage III or stage IV melanoma without brain metastases. TMZ (75 mg/m²/d) for 6 weeks was followed by a 2-week break, and thalidomide at 200 to 400 mg/d. Thirty-eight patients were treated, and 10 patients (26%) showed partial response (PR); four other patients showed minor response and three had a mixed response. The most common side effects included rash, constipation, vomiting, dizziness, dyspnea, fatigue, headache, drowsiness, hyperglycemia, and elevation of liver enzymes.

A randomized phase II study compared TMZ alone, TMZ combined with interferon alfa-2b and TMZ combined with thalidomide.⁷⁷ One hundred eighty-one patients with metastatic melanoma were randomly assigned to one of the three regimens. Response or disease stabilization occurred in 25% of the patients treated with TMZ plus thalidomide combination, 20% receiving TMZ alone and 21% of those given TMZ plus interferon. Median survival was 7 months for the TMZ/thalidomide arm, 5 months for the TMZ alone arm, and 8 months for the TMZ plus interferon (not significantly different across the three groups).

At present, the role of thalidomide in melanoma is investigational and its use should be restricted to clinical trials. Again, given the disappointing results when used alone, thalidomide should be studied further in combination with chemotherapeutic agents with known activity in this disease. Results of ongoing and future clinical trials will further define its role.

Renal Cell Cancer

Thalidomide has shown promising activity in renal cell carcinoma (RCC) in several clinical trials. Stebbing et al⁶⁷ evaluated the use of high-dose oral thalidomide (600 mg daily) in 25 patients with advanced renal carcinoma, who had either progressed on or were not suitable for immunotherapy. Of the 22 assessable patients, two showed PRs

Table 2. Clinical Trials of Thalidomide Alone or in Combination for Solid Tumors

Disease	Trial Type	No. of Patients	Regimen	Thal Dose (mg/day)	Efficacy (CR or PR)	Side Effects
Prostate cancer						
Figg et al ⁶⁰	Phase II randomized	63	Thal	200-1,200	27%	Fatigue, hyperglycemia, pulmonary toxicity, thrombotic events
Drake et al ⁶¹	Phase II	20	Thal	100	15%	Constipation, morning drowsiness, dizziness, neuropathy, rash
Figg et al ⁶²	Phase II	36	Thal + docetaxel	200	53%	Constipation, dizziness, edema, fatigue, mood changes, peripheral neuropathy
Breast cancer						
Baldas et al ⁶³	Phase II	28	Thal	200-800 or 1,200	No true PR or CR	Constipation, somnolence, fatigue, peripheral neuropathy, dizziness and instability, dry mouth, skin rash, nausea
Eisen et al ⁶⁴	Phase II	12	Thal	100	NR	Lethargy, neuropathy
Kaposi's sarcoma						
Fife et al ⁶⁵	Phase II	17	Thal	100	35%	
Little et al ⁶⁶	Phase II	20	Thal	200-1,000	47%	Neuropathy, depression, somnolence, fatigue
Renal cell cancer						
Stebbing et al ⁶⁷	Phase II	25	Thal	600	9%	Lethargy, constipation, neuropathy
Motzer et al ⁶⁸	Phase II	26	Thal	200-800	62% (SD only)	Dyspnea, neuropathy, thrombosis, fatigue, rash
Daliani et al ⁶⁹	Pilot	20	Thal	200-1,200	10%	Constipation, somnolence, fatigue, peripheral neuropathy
Escudier et al ⁷⁰	Phase II	40	Thal	400-1,200	5%	Fatigue, constipation, lethargy, neuropathy, thromboembolism
Minor et al ⁷¹	Phase II	29	Thal	400-1,200	5%	Somnolence, constipation
Brain						
Fine et al ⁷²	Phase II	36	Thal	800-1,200	12% (33% SD)	Constipation, sedation, neuropathy
Short et al ⁷³	Phase II	18	Thal	100	6%	Neuropathy
Marx et al ⁷⁴	Phase II	42	Thal	100-500	5% (42% SD)	Fatigue
Fine et al ⁷⁵	Phase II	40	Thal + BCNU	800-1,200	24%	Sedation, myelosuppression
Melanoma						
Hwu et al ⁷⁶	Phase II	38	Thal + Temozolomide	100-250	10%	Rash, constipation, vomiting, dizziness, dyspnea, fatigue, headache, drowsiness, hyperglycemia, liver enzyme elevation
Danson et al ⁷⁷	Phase II	60 (Thal arm)	TMZ v thal/TMZ v IFN/TMZ	100	25%	Constipation, lethargy

Abbreviations: Thal, thalidomide; CR, complete response; PR, partial response; NR, no response; SD, stable disease; BCNU, carmustine; TMZ, temozolomide; IFN, interferon.

(9%), seven (32%) had stable disease for more than 6 months, and five (23%) other patients had stable disease for between 3 and 6 months. In patients with stable disease for 3 or more months or objective response, a significant decrease in serum TNF- α levels was seen.

Several recent studies have looked at escalating doses of thalidomide to as high as 1,200 mg/d (Table 2). In one phase

II trial, 40 patients with metastatic renal cell cancer (RCC) were treated at a starting dose of 400 mg, followed by a 400 mg increment to 800 mg and then to 1,200 mg with 6 to 12 weeks at each dose level.⁷⁰ Two PRs were observed (5%) and disease remained stable in nine patients after 6 months. Median survival was 10 months. There was significant toxicity, mainly fatigue, constipation, lethargy, neuropathy,

and venous thromboembolism. In another study, 20 patients with metastatic RCC were treated at doses starting at 200 mg escalating to 1,200 mg/d.⁶⁹ Two patients achieved a PR, and nine had stable disease for a median of 14 months. The most common, but reversible toxicities were constipation, somnolence, and fatigue. Median time to progression was 4.7 months. Minor et al⁷¹ studied 29 patients with metastatic RCC using escalating doses of thalidomide (400 mg/d and increased as tolerated to 1,200 mg/d). Among the 24 patients assessable for response, one had PR, one had minor response, and two patients had stable disease for over 6 months. Similar side effects were seen and doses over 800 mg/d were difficult to achieve in this trial.

Two studies have used lower doses of thalidomide. Motzer et al⁶⁸ treated 26 patients with advanced RCC with thalidomide at doses between 200 and 800 mg/d. Fifteen had prior nephrectomy, 11 had no prior systemic therapy, and 15 had received one prior systemic regimen. Of 25 assessable patients, the best response was stable disease in 16 patients. Progression-free survival at 6 months was 32%; 57% were alive at 1 year. Eisen et al⁶⁴ treated 18 patients with low-dose thalidomide (100 mg/d) and observed three PRs among 18 treated patients. An additional three patients had stabilization of their disease, and most patients tolerated therapy well.

Combination trials with thalidomide and other active agents are ongoing. Serious adverse events have been reported with the combination of interferon and thalidomide, including seizures and visual disturbances.⁸⁰ A randomized trial conducted by the Eastern Cooperative Oncology Group comparing interferon plus thalidomide versus interferon alone has recently met accrual and results are awaited. Thalidomide has been tested in combination with IL-2 and the combination appears to have activity with acceptable toxicity.⁸¹ Amato et al⁸² used thalidomide (400 mg daily) with interleukin-2 (7 mIU/m² subcutaneous days 1 to 5 on weeks 1 to 4, repeated every 6 weeks) in 37 patients. Of 36 assessable patients, there was one complete response and 14 PRs for a response rate of 42%. A recently initiated multicenter, randomized, double-blind study is comparing the efficacy and safety of thalidomide plus low-dose IL-2 versus low-dose IL-2 alone versus thalidomide alone in subjects with previously untreated metastatic renal cell cancer.

In summary, thalidomide as a single-agent has shown limited activity in RCC. Activity in combination with IL-2 is promising, but results of the ongoing randomized trial are needed. Thalidomide may be of benefit in combination with other active, synergistic agents, and this option needs to be explored in future clinical trials.

Kaposi's Sarcoma

The observation of Kaposi's sarcoma (KS) lesions improving in some individuals who were receiving thalidomide therapy for HIV-related oral ulcers, combined

with the highly vascular nature of this tumor, formed the rationale for evaluating thalidomide in the treatment of KS. In a phase II study, 17 male HIV-seropositive patients with histopathologically diagnosed KS were treated with thalidomide 100 mg orally once nightly for 8 weeks.⁶⁵ Six of 17 patients achieved a PR associated with reduction in HHV-8 DNA load to undetectable levels in three of the responders. Thalidomide has also shown benefit in non-HIV-related KS.⁸³ Little et al⁶⁶ evaluated thalidomide in a phase II study with doses ranging from 200 to 1,000 mg/d given up to a year along with antiretroviral therapy. Eight of the 17 assessable patients achieved a PR, and an additional two patients had stable disease. Since most patients also received concurrent antiretroviral therapy in this trial, the investigators recommend caution in interpreting results. Additional studies are needed to define the role of thalidomide in KS.

Brain Tumors

Thalidomide was evaluated in patients with anaplastic mixed glioma, anaplastic astrocytoma, or glioblastoma multiforme who had tumor progression after radiotherapy with or without chemotherapy in a phase II trial.⁷² Patients were treated with escalating doses of thalidomide starting at 800 mg/d, with increases in dose by 200 mg/d every 2 weeks to a final daily dose of 1,200 mg. Among 39 patients, there were two objective radiographic PRs (6%), two minor responses (6%), and 12 patients with stable disease (33%). Eight patients were alive more than 1 year after starting thalidomide, although almost all had tumor progression.

In another phase II trial, 18 patients with recurrent high grade gliomas were treated with 100 mg a day of thalidomide.⁷³ All patients had failed radiotherapy and chemotherapy with procarbazine, lomustine, and vincristine and/or temozolomide regimens. Six patients died before response could be fully assessed, and were classified as non-responders. Of the 12 patients treated for more than 4 weeks, only one patient had clinical and radiologic response (PR); two patients had stable disease for 2 and 4 months, respectively. The median survival from the start of thalidomide was 2.5 months. Though the efficacy was low in this study, the authors felt that thalidomide should be further investigated in combination with other agents and at an earlier stage of disease.

Marx et al⁷⁴ published the results of a phase II trial in recurrent glioblastoma multiforme. Forty-two patients were treated with 100 mg/d, increased at weekly intervals by 100 mg to a maximum-tolerated dose of 500 mg/d (median maximum-tolerated dose was 300 mg/d). Of the 38 assessable patients, two patients (5%) achieved a PR and 16 (42%) had stable disease. The median survival was 31 weeks and the 1-year survival was 35%. Responding patients had some stabilization or improvement in quality of life scores or performance status. Overall, the drug

was well tolerated with no grade 4 toxicities and no treatment related deaths.

Glass et al⁸⁴ combined thalidomide with carboplatin for recurrent glioma. Thalidomide up to a dose of 300 mg/d was given continuously along with six cycles of carboplatin. Sixty-four patients were enrolled and 46 were assessable. Five patients (11%) had a PR and 28 had stable disease. The estimated median survival was 40 weeks and the median response duration was 24 weeks. Fine et al⁷⁵ used the combination of thalidomide and carmustine in patients with recurrent high-grade gliomas. Patients with high-grade glioma and radiographic evidence of tumor progression after standard surgery, radiation, and chemotherapy were treated with carmustine 200 mg/m² on day 1 every 6 weeks, and thalidomide was started at 800 mg/d and increased to a maximal dose of 1,200 mg/d as tolerated. Of 40 patients treated, 24% had an objective radiographic response. The combination was well tolerated, with mild myelosuppression and mild to moderate sedation being the most common side effects.

These results show that thalidomide as a single agent has only marginal activity in high-grade gliomas, with PR rates that are less than 10%. Given the inherent problems in assessing response in this patient population and minimal effects on survival, the use of thalidomide for high-grade gliomas should probably be considered only in the context of clinical trials. Also, given the disappointing single-agent activity, combinations with other active agents should be explored for synergistic activity.

Prostate Cancer

Thalidomide was studied in a phase II study evaluating two dosing regimens of thalidomide (200 mg/d v 1,200 mg/d) in androgen-independent prostate cancer. Sixty-three patients refractory to combined androgen deprivation were studied; 50 received 200 mg/d of thalidomide and 13 patients received 1,200 mg/d of thalidomide.⁶⁰ A 50% or greater decrease in prostate-specific antigen (PSA) was noted in 18% of patients on the low-dose arm; no patients in the high-dose arm responded.

In another study, 20 patients with androgen-independent prostate cancer were treated with thalidomide 100 mg once daily. Three patients (15%) showed a decline in serum PSA of at least 50%.⁶¹ Progressive disease was associated with increase in the levels of serum basic fibroblast growth factor (bFGF) and VEGF while responding patients had decline in levels of these angiogenic cytokines. Adverse effects included constipation, drowsiness, dizziness, and skin rash. Preclinical studies have suggested that thalidomide may increase the secretion of PSA from tumor cells and confound efficacy evaluation.⁸⁵

Thalidomide was also studied in combination with docetaxel in a randomized phase II study in patients with androgen independent prostate cancer.⁶² Thirty-five percent of the patients (six of 17) receiving docetaxel alone and

53% (19 of 36) of those receiving docetaxel and thalidomide had a PSA decrease of at least 50%. There was an increased rate of thrombotic events in the combination arm.

These studies show that thalidomide decreases PSA levels in 15% to 20% of patients with hormone refractory prostate cancer. However, more studies are needed to determine the usefulness of this agent in routine clinical practice in this setting, given that the response rate is small and other meaningful assessments of tumor burden need to be done.

Breast Cancer

Tumor angiogenesis has prognostic value in invasive breast cancer and it has been correlated with its metastatic potential.⁸⁶ In a phase II randomized study, Baidas et al⁶³ treated 28 patients with progressive metastatic breast cancer either daily 200 mg of thalidomide or 800 mg to be escalated to 1,200 mg. No patient had a true PR or complete response in this study at either of the dose levels. Toxicities including somnolence and neuropathy required dose reductions, especially in the higher dose arm. Others have also noted a lack of significant efficacy of low or higher doses of thalidomide in the treatment of breast cancer.⁶⁴ Thalidomide, at least when used alone, is ineffective in breast cancer. It is unclear if it will have any role as part of combination regimens.

Other Solid Tumors

Thalidomide has been studied in combination with irinotecan in metastatic colorectal cancer with some responses. Interestingly, thalidomide ameliorated the common side effect of irinotecan, namely diarrhea, enabling a larger number of patients to complete planned therapy.⁸⁷ Responses have been observed in patients with unresectable hepatocellular carcinoma, with thalidomide alone or in combination with Cox-2 inhibitors, capecitabine, or other agents. Phase II studies with thalidomide have also been conducted in malignant mesothelioma, small-cell lung cancer, and metastatic neuroendocrine tumors. In addition, case reports and pilot studies have documented isolated responses with thalidomide in other solid tumors, such as ovarian cancer.⁸⁸ Results so far do not support off-study use of thalidomide in any of these malignancies.

Thalidomide may also have a role in the palliative setting. Improved appetite, weight gain, and improvement in quality-of-life scores have been seen with thalidomide therapy in patients with advanced malignancies.⁸⁹ However, we do not feel that therapy with this agent for this purpose can be recommended at this time.

Hematologic Malignancies

The focus of this review is on non-plasma-cell malignancies, and so a detailed review of the current status of thalidomide in myeloma and related disorders is beyond the scope of this article. Briefly, several trials confirm that thalidomide as a single-agent produces response rates in approximately 25% to 35% of patients with relapsed refrac-

Table 3. Clinical Trials in Hematologic Malignancies Other Than Myeloma

Disease (regimen)	Trial Type	Assessable Patients	Thalidomide Starting Dose (mg/day)	Thalidomide Maximum Dose (mg/day)	Efficacy (CR or PR)	Major Side Effects
Waldenström's macroglobulinemia (thalidomide) ¹⁰³	Phase II	20	200	600	20%	Constipation, somnolence, fatigue, mood changes, peripheral neuropathy, skin rash
Waldenström's macroglobulinemia (BLT-D) ¹⁰³	Phase II	12	200	200	33%	Constipation, somnolence, fatigue, mood changes, peripheral neuropathy, skin rash
Waldenström's macroglobulinemia (BLT-D) ¹⁰⁴	Phase II	12	200	200	83%	Constipation, peripheral neuropathy, thrombosis
Primary systemic amyloidosis ¹⁰⁵	Phase I/II	16	200	600	25% (hematologic response)	Fatigue, neuropathy, constipation
Acute myelogenous leukemia ¹⁰⁶	Phase I/II	20	200	400	20%	Fatigue, constipation, rash, neuropathy
Myelodysplastic syndrome ¹⁰⁷	Phase I/II	83	200	400	31%	Fatigue, constipation, dyspnea, fluid retention, dizziness, rash, neuropathy, fever, headache
Myelodysplastic syndrome ¹⁰⁸	Phase I/II	30	100	400	30%	Constipation, fatigue, dizziness, dyspnea, neuropathy
Myelodysplastic syndrome ¹⁰⁹	Phase II	34	100	400	27%	Fatigue, rash
Non-Hodgkin's lymphoma ¹¹⁰	Phase II	12	200	800	8% CR, 25% SD	Fatigue, peripheral neuropathy
Myelofibrosis with myeloid metaplasia ¹¹¹	Phase II	15	200	400	80% (platelet count improved)	Fatigue, constipation, thrombocytosis, neuropathy, rash sedation.
Myelofibrosis with myeloid metaplasia ¹¹²	Pilot	12	100	600	60%	Constipation, fatigue, somnolence, neuropathy
Myelofibrosis with myeloid metaplasia ¹¹³	Phase II	13	100	400	43% (improved anemia)	Somnolence, fatigue, constipation

Abbreviations: CR, complete response; PR, partial response; BLT-D, clarithromycin, thalidomide, and dexamethasone; SD, stable disease.

tory myeloma.^{9,13} The median duration of response is 1 year.^{90,91} Response rates in relapsed disease increase to approximately 50% with the addition of corticosteroids,⁹² and to over 65% with the addition of corticosteroids and cyclophosphamide.⁹³ Several other combination chemotherapy regimens containing thalidomide are being studied including dexamethasone, thalidomide, cisplatin, adriamycin, cyclophosphamide and etoposide,⁹⁴ clarithromycin 500 mg twice daily, low-dose thalidomide 50 mg/d, and dexamethasone,⁹⁵ melphalan, thalidomide, and dexamethasone,⁹⁶ and melphalan plus thalidomide.⁹⁷ In newly diagnosed myeloma, the combination of thalidomide plus dexamethasone has responses in the range of 65% to 70%.^{98,99} Thalidomide alone or in combination is also being studied in early stage myeloma,¹⁰⁰ as maintenance therapy for patients who have undergone autologous stem-cell transplantation¹⁰¹ and as consolidation therapy following autologous stem-cell transplantation in an attempt to convert partial remission to CR.¹⁰²

In Waldenström's macroglobulinemia, thalidomide as a single-agent had a response rate of 25% in a small phase II clinical trial¹⁰³ (Table 3). The combination of clarithromycin (500 mg bid), low-dose thalidomide (200 mg once daily), and dexamethasone (40 mg once per week) has also been studied in two trials,¹⁰⁴ and demonstrated activity in this disease. Activity in primary amyloidosis is being investigated,¹⁰⁵ but preliminary reports suggest higher rate of adverse events in this group.

The encouraging results seen with other plasma cell proliferative disorders have led to the initiation of clinical trials evaluating the role of thalidomide in primary systemic amyloidosis. Seldin et al¹¹⁴ presented the results of a phase I/II trial of thalidomide as a single agent in twelve patients with amyloidosis. Five of eleven patients had hematologic improvement. Three patients had stable disease and three had progressive disease. However, in this trial as well as in other studies, significant toxicities were observed with the use of thalidomide, especially at higher doses.

Based on current data, thalidomide is a standard treatment option for patients with relapsed myeloma, alone or in combination with corticosteroids. It can be considered for patients with Waldenström's macroglobulinemia who are refractory to other standard regimens. Its role in combination with other active chemotherapeutic agents, as initial therapy and as maintenance, following transplantation in myeloma and in the therapy of primary systemic amyloidosis is investigational.

Myelofibrosis With Myeloid Metaplasia

Increased bone marrow angiogenesis has been demonstrated in patients with myelofibrosis/myeloid metaplasia (MMM), leading to the evaluation of thalidomide in this condition (Table 3).¹¹⁵ In a prospective study of 15 patients with MMM conducted at the Mayo Clinic (Rochester, MN), treatment with thalidomide resulted in increased

platelet counts (12 of 15 patients), increased hemoglobin level (three of 15 patients), modest decrease in spleen size (three of 12 patients), increased bone marrow megakaryopoiesis (five of nine patients), and decreased bone marrow angiogenesis (two of nine patients).¹¹¹ Although improvements in cytopenias were seen in this trial at conventional doses of thalidomide (200 to 400 mg/d), serious myeloproliferative reactions, including marked leucocytosis and thrombocytosis were observed in a few patients.¹¹⁶ In another study of 13 assessable patients who received more than 30 days of therapy (100-400 mg/d), Barosi et al¹¹³ noted improvement in anemia in three (43%) of seven patients, improvement in thrombocytopenia in two (67%) of three patients, and reduction in splenomegaly in four patients (31%). Serious myeloproliferative reactions were noted in this study as well. These initial studies concluded that lower doses of the drug need to be tested to minimize toxicity. There was a suggestion in the Mayo Clinic study that there was no loss of efficacy in patients in whom the dose was reduced to as low as 50 mg/d.

Reduction in bone marrow angiogenesis have been noted in patients treated with thalidomide along with reduction in the angiogenic cytokines VEGF and fibroblast growth factor in responding patients.¹¹² There has been one negative study, in which significant side effects were seen with no beneficial responses.¹¹⁷ In a pooled-analysis of the data from five phase II trials including 62 patients, a small but clear improvement of disease severity with thalidomide therapy was noted.¹¹⁸ Twenty-nine percent of patients with moderate to severe anemia showed an increase in hemoglobin or reduction/abolishment of blood transfusion requirements, 38% with moderate to severe thrombocytopenia had an increase in platelet counts, and 41% demonstrated a reduction in splenomegaly. Nearly 18% of the patients had a myeloproliferative reaction with leukocytosis and/or thrombocytosis. Sixty-six percent of the patients discontinued the drug before 6 months of treatment as a result of intolerance.

Based on the promising results with single-agent therapy, the combination of thalidomide with corticosteroids was evaluated in 21 symptomatic patients (hemoglobin level < 10 g/dL or symptomatic splenomegaly).¹¹⁹ Patients received low-dose thalidomide (50 mg/d) to minimize serious myeloproliferative reactions along with a 3-month oral prednisone taper (beginning at 0.5 mg/kg/d). The combination was well tolerated, with all but one patient completing 3 months of treatment. An objective clinical response in the form of improvement in anemia was seen in 13 (62%) patients. Improvement in platelet count was seen in four of eight patients with thrombocytopenia. In four of 21 patients (19%), spleen size decreased by more than 50%. Responses observed were durable after discontinuation of corticosteroids in most of the patients.

In summary, low-dose thalidomide (50 mg/d) with prednisone is a reasonable therapeutic choice for patients with MMM who have cytopenias as the dominant manifestation of their disease. Further studies are needed for MMM patients with marked splenomegaly.

Myelodysplastic Syndrome

Several studies have been conducted examining the activity of thalidomide in myelodysplastic syndrome (MDS) and initial results are promising (Table 3). In a small study evaluating the effect of thalidomide in hematologic conditions associated with increased angiogenesis, Bertolini et al¹²⁰ noted clinical responses in two of the five patients with MDS they studied. They also noted a simultaneous decrease in the angiogenic cytokines bFGF and VEGF with response in these patients. Raza et al¹⁰⁷ studied 83 patients with MDS and noted hematologic improvement among 31% of assessable patients including transfusion independence in nine patients who were previously transfusion dependant. In another study, 30 patients with MDS were treated with 100 to 400 mg/d of thalidomide resulting in hematologic improvement in a third of the patients.¹⁰⁸ They studied the levels of apoptosis, macrophage number, microvessel density, TNF- α , transforming growth factor beta (TGF- β), IL-6, VEGF, and bFGF in the serum, bone marrow (BM) plasma and BM biopsies before and after therapy, and found a decrease in only BM TGF- β . In the latter two studies, patients with higher platelet counts and lower blast percentage at initiation of therapy were likely to respond. Finally, Strupp et al¹⁰⁹ studied 34 patients with MDS; five T-refractory anemia with excess blasts in transformation (RAEB-T), four refractory anemia with excess blasts, three chronic myelo-monocytic leukemia, six refractory anemia with ringed sideroblasts, and 16 refractory anemia with 400 mg/d of thalidomide. Nineteen of 29 assessable patients had hematologic improvement; six patients (four refractory anemia, two chronic myelo-monocytic leukemia) showed progressive disease, and four patients showed stable disease. Nine of the responders achieved partial remission with granulocytes \geq 1,500/microl, Hb > 11 g/dL, and platelets \geq 100,000/microl; four patients became transfusion independent.¹⁰⁹ Strupp et al¹²¹ have also recently shown normalization of counts with cytogenetic responses in three patients with MDS following therapy with thalidomide. Combination of darbopoietin with thalidomide in patients with MDS was associated with increased thromboembolic events in a small study.¹²²

Although thalidomide therapy is associated with improvements in cytopenias in patients with MDS, more data are still needed on effects of the drug on the clonal tumor cell population, cytogenetic responses, and progression of MDS to acute myeloid leukemia (AML). A randomized trial is currently ongoing to determine the role of thalidomide in MDS. Based on the available data it would be reasonable

to initiate a therapeutic trial of thalidomide in patients with refractory cytopenias secondary to MDS who are not candidates for ongoing clinical trials. The new thalidomide analog (CC-5013) may have a better therapeutic effect in this disease compared to thalidomide.

Acute Myelogenous Leukemia

In vitro studies on leukemia cell lines have demonstrated retinoid-like activity for thalidomide leading to differentiation of K562 leukemia cell line, as well as cytotoxic effect by the thalidomide metabolites.¹²³ This, in addition to the demonstration of increased bone marrow angiogenesis in patients with acute leukemias,¹²⁴ have led to the evaluation of thalidomide for the treatment of acute leukemias. Steins et al,¹⁰⁶ in a phase I/II dose-escalating trial, studied the efficacy of thalidomide in 20 patients with AML. Thirteen patients who completed the trial received doses of 200 to 400 mg daily for at least 1 month. Adverse events were similar to those in other studies. Four patients had a reduction of at least 50% in the blast cell infiltration of the bone marrow with improvement in peripheral blood counts. The responses lasted a median of 3 months (range, 1 to 8 months). They observed a significant decrease in the microvessel densities in the responding patients treated with thalidomide, which was accompanied by declining plasma levels of bFGF.

At this time, despite preliminary results from Steins et al,¹²² there are limited data to support the use of thalidomide in AML outside of clinical trials.

Non-Hodgkin's Lymphoma

The role of angiogenesis is increasingly recognized in the pathogenesis of lymphoid malignancies.¹²⁵ Elevated serum levels of VEGF and bFGF have been correlated with poor prognosis in patients with non-Hodgkin's lymphoma (NHL).¹²⁶ Preliminary results are available from a phase II study of thalidomide in patients with recurrent NHL and Hodgkin's disease without CNS involvement, 18 patients received thalidomide at a starting dose of 200 mg daily.¹¹⁰ The dose was escalated by 200 mg every 2 weeks until a maximum of 800 mg based on toxicity and tolerability. Median age was 66 years (range, 30 to 78 years) and the median number of prior treatments was five (range, 3 to 7 treatments). The diagnoses included small lymphocytic lymphoma (three patients), follicular small cleaved (three patients), large B-cell lymphoma (six patients), mantle-cell lymphoma (two patients), Hodgkin's disease (two patients), and one each of mucosa-associated lymphoid tumors (MALT) and peripheral T-cell lymphoma. A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was reached in seven (41%), five (29%), two (11%), and three (17%) patients respectively, and one patient is still on escalating doses. Of 12 assessable patients, one patient achieved CR (refractory MALT lymphoma of the stomach) and three patients had

stable disease. Grade 2/3 neurologic toxicity was observed in six patients; grade 2/3 fatigue occurred in 16 patients. Reductions of plasma levels of VEGF and bFGF were observed in the one patient who achieved CR. No significant decreases in plasma levels of angiogenic factors were observed in patients with stable disease.

Thalidomide has recently been reported to be effective in the treatment of angioimmunoblastic lymphadenopathy.¹²⁷ There have been case reports of patients with mantle-cell lymphoma responding to thalidomide.¹²⁸

We feel that thalidomide has not shown significant activity in NHL and available data are too premature to make definite conclusions. However, clinical trials in MALT and mantle-cell lymphoma may be of interest.

Future Directions

In clinical trials with thalidomide so far, responses as dramatic as those observed in multiple myeloma have not been observed in other hematologic malignancies and solid tumors. Nevertheless, thalidomide has shown promising activity in two hematologic malignancies, namely MMM and MDS. In MMM, the addition of prednisone to low-dose thalidomide appears to prevent serious myeloproliferative reactions and improve efficacy. Trials in solid tumors again have demonstrated useful activity for this drug, especially in Kaposi's sarcoma and malignant melanoma. The efficacy of adding thalidomide to other effective drug combinations continues to be explored in various malignancies.

Compared to myeloma, the amount of data is still limited in almost all other malignancies in which thalidomide has shown promising activity. Ongoing trials, especially those evaluating combination of thalidomide with other active cytotoxic agents, will define the role of thalidomide in the therapy of non-plasma-cell malignancies.

Even though the current prescribing system is designed to prevent any possible fetal exposure with this agent, the risk of such an event and the potential for the congenital deformities exist. There are research efforts underway to identify or develop thalidomide analogs with improved antitumor activity without the teratogenic side effects. One such analog, CC-5013, has already shown promise in myeloma and myelodysplastic syndrome and is being tested in several clinical trials.

Acknowledgment

We thank Drs Ayalew Tefferi, Ruben Mesa, Henry C. Pitot IV, Jan C. Buckner, and Patrick C. Burch for their valuable input into the current clinical uses of thalidomide in their respective fields of research and practice.

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

1. Lenz W: Thalidomide and congenital abnormalities. *Lancet* 1:45, 1962
2. McBride WG: Thalidomide and congenital abnormalities. *Lancet* 2:1358, 1961
3. Sheskin J: Thalidomide in the treatment of lepra reactions. *Clin Pharmacol Ther* 6:303-306, 1965
4. Hamuryudan V, Mat C, Saip S, et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 128:443-450, 1998
5. Jacobson JM, Greenspan JS, Spritzler J, et al: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. *N Engl J Med* 336:1487-1493, 1997
6. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al: Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. *AIDS* 10:1501-1507, 1996
7. Parker PM, Chao N, Nademanee A, et al: Thalidomide as salvage therapy for chronic graft-versus-host disease. *Blood* 86:3604-3609, 1995
8. Zeldis JB, Williams BA, Thomas SD, et al: S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. *Clin Ther* 21:319-330, 1999
9. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. *N Engl J Med* 341:1565-1571, 1999
10. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. *Blood* 98:492-494, 2001
11. Rajkumar SV, Fonseca R, Dispenzieri A, et al: Thalidomide in the treatment of relapsed multiple myeloma. *Mayo Clin Proc* 75:897-902, 2000
12. Rajkumar SV, Gertz MA, Kyle RA, et al: Current therapy for multiple myeloma. *Mayo Clin Proc* 77:813-822, 2002
13. Rajkumar SV, Mesa R, Tefferi A: A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. *J Hematother Stem Cell Res* 11:33-47, 2002
14. Rogerson G: Thalidomide and congenital abnormalities. *Lancet* 1:691, 1962
15. Grabstad H, Golbey R: Clinical experience with thalidomide in patients with cancer. *Clin Pharmacol Ther* 6:298-302, 1965
16. Olson KB, Hall TC, Horton J, et al: Thalidomide (N-phthaloylglutamide) in the treatment of advanced cancer. *Clin Pharmacol Ther* 6:292-297, 1965
17. Folkman J: Tumor angiogenesis: Therapeutic implications. *N Engl J Med* 285:1182-1186, 1971
18. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med* 333:1757-1763, 1995
19. O'Reilly MS, Holmgren L, Chen C, et al: Angiostatin induces and sustains dormancy of human primary tumors in mice. *Nat Med* 2:689-692, 1996

20. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. *Cell* 88:277-285, 1997
21. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A* 91:4082-4085, 1994
22. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. *Exp Eye Res* 64:971-978, 1997
23. Eriksson T, Bjorkman S, Roth B, et al: Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man. *J Pharm Pharmacol* 52:807-817, 2000
24. Chen TL, Vogelsang GB, Petty BG, et al: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. *Drug Metab Dispos* 17:402-405, 1989
25. Figg WD, Raju S, Bauer KS, et al: Pharmacokinetics of thalidomide in an elderly prostate cancer population. *J Pharm Sci* 88:121-125, 1999
26. Piscitelli SC, Figg WD, Hahn B, et al: Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 41:2797-2799, 1997
27. Teo SK, Scheffler MR, Kook KA, et al: Thalidomide dose proportionality assessment following single doses to healthy subjects. *J Clin Pharmacol* 41:662-667, 2001
28. Teo SK, Harden JL, Burke AB, et al: Thalidomide is distributed into human semen after oral dosing. *Drug Metab Dispos* 29:1355-1357, 2001
29. Tsambaos D, Bolsen K, Georgiou S, et al: Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene. *Arch Dermatol Res* 286:347-349, 1994
30. Stirling DI: Pharmacology of thalidomide. *Semin Hematol* 37:5-14, 2000
31. Yaccoby S, Johnson CL, Mahaffey SC, et al: Antimyeloma efficacy of thalidomide in the SCID-hu model. *Blood* 100:4162-4168, 2002
32. Lu J, Palmer BD, Kestell P, et al: Thalidomide metabolites in mice and patients with multiple myeloma. *Clin Cancer Res* 9:1680-1688, 2003
33. Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. *Eur J Clin Pharmacol* 57:365-376, 2001
34. Aweeka F, Trapnell C, Chernoff M, et al: Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. *J Clin Pharmacol* 41:1091-1097, 2001
35. Lenz W: A short history of thalidomide embryopathy. *Teratology* 38:203-215, 1988
36. Lenz W: A personal perspective on the thalidomide tragedy. *Teratology* 46:417-418, 1992
37. Ghobrial IM, Rajkumar SV: Management of thalidomide toxicity. *J Support Oncol* 1:194-205, 2003
38. Hall VC, El-Azhary RA, Bouwhuis S, et al: Dermatologic side effects of thalidomide in patients with multiple myeloma. *J Am Acad Dermatol* 48:548-552, 2003

39. Rajkumar SV, Gertz MA, Witzig TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. *N Engl J Med* 343:972-973, 2000
40. Osman K, Comenzo R, Rajkumar SV: Deep vein thrombosis and thalidomide therapy for multiple myeloma. *N Engl J Med* 344:1951-1952, 2001
41. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. *Blood* 98:1614-1615, 2001
42. Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. *Blood* 100:1168-1171, 2002
43. Zangari M, Saghatifor F, Anaissie E, et al: Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. *Blood Coagul Fibrinolysis* 13:187-192, 2002
44. Harris E, Behrens J, Samson D, et al: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. *Br J Haematol* 122:160-161, 2003
45. Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. *Clin Cancer Res* 8:3377-3382, 2002
46. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. *Biochem Pharmacol* 55:1827-1834, 1998
47. Adeoti AG, Vega KJ, Dajani EZ, et al: Idiopathic esophageal ulceration in acquired immunodeficiency syndrome: Successful treatment with misoprostol and viscous lidocaine. *Am J Gastroenterol* 93:2069-2074, 1998
48. Moreira AL, Sampaio EP, Zmuidzinas A, et al: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. *J Exp Med* 177:1675-1680, 1993
49. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. *Blood* 96:2943-2950, 2000
50. Niwayama S, Turk BE, Liu JO: Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. *J Med Chem* 39:3044-3045, 1996
51. Thompson MA, Witzig T, Kumar S, et al: Plasma levels of tumor necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. *Br J Haematol* 123:305-308, 2003
52. Neben K, Mytilineos J, Moehler TM, et al: Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. *Blood* 100:2263-2265, 2002
53. Haslett PA: Anticytokine approaches to the treatment of anorexia and cachexia. *Semin Oncol* 25:53-57, 1998
54. Gad SM, Shannon EJ, Krotoski WA, et al: Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. *Lepr Rev* 56:35-39, 1985

55. McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. *Clin Exp Immunol* 99:160-167, 1995
56. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood* 98:210-216, 2001
57. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. *Immunopharmacology* 31:213-221, 1996
58. Keifer JA, Guttridge DC, Ashburner BP, et al: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. *J Biol Chem* 276:22382-22387, 2001
59. Noguchi T, Shimazawa R, Nagasawa K, et al: Thalidomide and its analogues as cyclooxygenase inhibitors. *Bioorg Med Chem Lett* 12:1043-1046, 2002
60. Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. *Clin Cancer Res* 7:1888-1893, 2001
61. Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. *Br J Cancer* 88:822-827, 2003
62. Figg WD, Arlen P, Gulley J, et al: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. *Semin Oncol* 28:62-66, 2001
63. Baidas SM, Winer EP, Fleming GF, et al: Phase II evaluation of thalidomide in patients with metastatic breast cancer. *J Clin Oncol* 18:2710-2717, 2000
64. Eisen T, Boshoff C, Mak I, et al: Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. *Br J Cancer* 82:812-817, 2000
65. Fife K, Howard MR, Gracie F, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. *Int J STD AIDS* 9:751-755, 1998
66. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 18:2593-2602, 2000
67. Stebbing J, Benson C, Eisen T, et al: The treatment of advanced renal cell cancer with high-dose oral thalidomide. *Br J Cancer* 85:953-958, 2001
68. Motzer RJ, Berg W, Ginsberg M, et al: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. *J Clin Oncol* 20:302-306, 2002
69. Dalani DD, Papanicolaou CN, Thall PF, et al: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. *Cancer* 95:758-765, 2002
70. Escudier B, Lassetz N, Couanet D, et al: Phase II trial of thalidomide in renal-cell carcinoma. *Ann Oncol* 13:1029-1035, 2002
71. Minor DR, Monroe D, Damico LA, et al: A phase II study of thalidomide in advanced metastatic renal cell carcinoma. *Invest New Drugs* 20:389-393, 2002
72. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. *J Clin Oncol* 18:708-715, 2000
73. Short SC, Traish D, Dowe A, et al: Thalidomide as an anti-angiogenic agent in relapsed gliomas. *J Neurooncol* 51:41-45, 2001
74. Marx GM, Pavlakis N, McCowatt S, et al: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. *J Neurooncol* 54:31-38, 2001
75. Fine HA, Wen PY, Maner EA, et al: Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. *J Clin Oncol* 21:2299-2304, 2003
76. Hwu WJ, Krown SE, Menell JH, et al: Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: A Phase II trial. *Proc Am Soc Clin Oncol* 21:344a, 2002 (abstr 1372)
77. Danson S, Lorigan P, Arance A, et al: Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. *J Clin Oncol* 21:2551-2557, 2003
78. Reinz AB, Richter M, Fernandes S, et al: A phase II study of thalidomide in patients with metastatic malignant melanoma. *Proc Am Soc Clin Oncol* 22:720, 2003 (abstr 2895)
79. Hwu WJ, Krown SE, Menell JH, et al: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. *J Clin Oncol* 21:3351-3356, 2003
80. Nathan PD, Gore ME, Eisen TG: Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. *J Clin Oncol* 20:1429-1430, 2002
81. Olencki T, Malhi S, Mekhail T, et al: Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). *Proc Am Soc Clin Oncol* 22:387, 2003 (abstr 1554)
82. Amato RJ, Schell J, Thompson N, et al: Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). *Proc Am Soc Clin Oncol* 22:387a, 2003
83. de Medeiros BC, Rezuke WN, Ricci A Jr, et al: Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. *Acta Haematol* 104:115-118, 2000
84. Glass J, Gruber ML, Nirenberg A: Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme. *Proc Am Soc Clin Oncol* 18:551, 1999
85. Dixon SC, Kruger EA, Bauer KS, et al: Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. *Cancer Chemother Pharmacol* 43:S78-S84, 1999 (suppl)
86. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. *N Engl J Med* 324:1-8, 1991
87. Govindarajan R: Irinotecan and thalidomide in metastatic colorectal cancer. *Oncology (Huntingt)* 14:29-32, 2000
88. Abramson N, Stokes PK, Luke M, et al: Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide. *J Clin Oncol* 20:1147-1149, 2002
89. Mahmoud FA, Walsh D, Davis M, et al: A dose titration study of thalidomide in cancer anorexia. *Proc Am Soc Clin Oncol* 22:789, 2003
90. Barlogie B, Spencer T, Tricot G, et al: Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). *Blood* 96:514a, 2000 (abstr 2213)
91. Kumar S, Gertz MA, Dispenzieri A, et al: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clin Proc* 78:34-39, 2003
92. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistant multiple myeloma. *Br J Haematol* 121:768-777, 2003
93. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. *Hematol J* 3:43-48, 2002
94. Tricot G, Siegel E, Langmaid C, et al: Angiochemotherapy (ACT) for multiple myeloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control. *Blood* 98:3531a, 2001
95. Coleman M, Leonard J, Lyons L, et al: BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. *Leuk Lymphoma* 43:1777-1782, 2002
96. Skralovic G, Elson P, Trebisky B, et al: Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. *Med Oncol* 19:219-226, 2002
97. Offidani M, Mele A, Marconi M, et al: Thalidomide plus melphalan in relapsed-refractory multiple myeloma. *Blood* 98:5000a, 2001
98. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *J Clin Oncol* 20:4319-4323, 2002
99. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. *J Clin Oncol* 21:16-19, 2003
100. Rajkumar SV, Gertz MA, Lacy MQ, et al: Thalidomide as initial therapy for early-stage myeloma. *Leukemia* 17:775-779, 2003

References 101-128 are included in the full-text version of this article, available on-line at www.jco.org.

They are not included in the PDF (via Adobe® Acrobat Reader®) version.

ERRATUM

The June 15, 2004, review article by Kumar et al contained an error in the title.
The correct title is "Thalidomide: Current Role in the Treatment of Non-Plasma Cell
Malignancies" (J Clin Oncol 22:2477-2488, 2004).
The online version of the title was corrected in departure from the print.

DOI: 10.1200/JCO.2004.06.932
